IV administered T-SIGn onco virus platform transforms adenovirus into “armed” vector. The therapy (NG-348), uses virus to transport two therapeutic genes directly into tumors to recruit immune cells into attacking targeted cancer cells. 2 partnerships with BMS.
- 2 programs in clinic with readouts in 2019 (ovarian cancer in comb w Paclitaxel, carcinomas in comb w nivolumab)
- 2 INDs in 2018 (NG-348 and NG-350A)
- 2 INDs in 2019 (NG-641 and NG-347)
Europe, United Kingdom
Phase l or ll, Pre-Clinical Stage
4-10 The Quadrant, Barton Lane
Abingdon, Oxfordshire, OX14 3YS
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.